AxoGen, Inc. Receives David J. Gury Company of the Year Award from BioFlorida
Award recognizes company’s contribution to Florida’s life sciences industry
ALACHUA, Fla., Oct. 18, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, has received the BioFlorida David J. Gury Company of the Year Award. The award, presented this week at the 20th anniversary BioFlorida Annual Conference, recognizes a company that has achieved significant milestones and has contributed to the growth of Florida's life sciences industry.
“Our platform for nerve repair can play an important role in helping surgeons improve the quality of life for patients with nerve damage,” said Karen Zaderej, president and CEO of AxoGen. “AxoGen has successfully evolved, expanding laterally from an initial niche product in a new market to a comprehensive nerve repair platform in an emerging market. We are grateful for the partnerships we have enjoyed on this journey; the University of Florida, the communities of Gainesville and Alachua, BioFlorida, and many others have provided support as we built a growing and sustainable life sciences business.”
AxoGen, founded in Alachua, FL in 2002 with technology licensed from the University of Florida, is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. AxoGen is redefining the way damaged peripheral nerves are repaired by developing new nerve repair products and expanded applications that bring meaningful solutions to current clinical challenges.
Under the leadership of Karen Zaderej, AxoGen has experienced 26 consecutive quarters of year-over-year double-digit growth and reported a record $15.2 million in revenue in Q2 2017, representing 46 percent growth over the prior year.
“AxoGen is a stand-out example of a Florida-based life science company that is changing health care around the world and inspiring our industry through ingenuity, innovation, and compelling financial and clinical results,” said Nancy K. Bryan, president and CEO of BioFlorida. “We are delighted to honor AxoGen with this award and look forward to their continued success.”
BioFlorida is the voice of Florida’s life sciences industry, representing nearly 6,000 establishments and research organizations in the biopharmaceutical, medical technology and bioagriculture sectors that collectively employ nearly 83,000 Floridians. The David J. Gury Company of the Year Award is named in honor of David Gury, one of the founding directors of BioFlorida.
AxoGen (AXGN) is a global leader in innovative surgical solutions for peripheral nerve injuries. AxoGen is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about restoring nerve function and quality of life to patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Damage to a peripheral nerve can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
AxoGen's platform for nerve repair features a comprehensive portfolio of products, including Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments, and Avive® Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a resorbable soft tissue covering to separate tissue layers and modulate inflammation in the surgical bed. Along with these core surgical products, AxoGen also offers AcroVal® Neurosensory & Motor Testing System and AxoTouch® Two-Point Discriminator. These evaluation and measurement tools assist health care professionals in detecting changes in sensation, assessing return of sensory, grip, and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom, and several other European and international countries.
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "projects," "forecasts," "continue," "may," "should," "will," and variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our assessment on our internal control over financial reporting, our growth, our 2017 guidance, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
Corporate & Investor Communications
Released October 18, 2017